Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in Hematologic Malignancies: Independent Conference Coverage of the 2021 ASCO Scientific Meeting
  • CME

Ian W. Flinn, MD, PhD
Shaji K. Kumar, MD
Eunice S. Wang, MD
Released: September 13, 2021
Back Next

References

  1. Moreau P, Sonneveld P, for the CASSIOPEIA Study Investigators. Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8004.
  2. Gay F, Mina R, Rota-Scalabrini D, et al. Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8002.
  3. Kaiser MF, Hall A, Walker K, et al. Depth of response and minimal residual disease status in ultra-high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8001.
  4. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361-2371.
  5. Hajek R, Moreau P, Augustson B, et al. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8034.
  6. Facon T, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8026.
  7. Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8042.
  8. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096-2107.
  9. Richardson PG, Perrot A, San-Miguel JF, et al. Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8017.
  10. Dimopoulos MA, Schjesvold F, Doronin V, et al. Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8020.
  11. Anderson LD Jr, Munshi NC, Shah N, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8016.
  12. Manier S, Kansagra AJ, Anderson LD Jr, et al. Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8036.
  13. Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8005.
  14. Terpos E, Badros A, Popat R, et al. Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8033.
  15. Bahlis NJ, Raje NS, Costello C, et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8006.
  16. Krishnan A, Garfall AL, Mateos M-V, et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8007.
  17. Berdeja JG, Krishnan A, Oriol A, et al. Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 8008.
  18. Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-731.
  19. Stein EM, Fathi AT, DiNardo CD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309-e319.
  20. Venugopal S, DiNardo CD, Takahashi K, et al. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7010.
  21. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225-234.
  22. Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178-184.
  23. DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90:732-736.
  24. DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018;378:2386-2398.
  25. Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135:463-471.
  26. Lachowiez CA, Borthakur G, Loghavi S, et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7012.
  27. Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1:1312-1323.
  28. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
  29. Pullarkat V, Pratz K, Dohner H, et al. Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7011.
  30. Pratz K, Jonas BA, Pullarkat V, et al. Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7018.
  31. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.
  32. Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia. 2017;31:1217-1220.
  33. Liersch R, Müller-Tidow C, Berdel WE, et al. Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use. Br J Haematol. 2014;165:17-38.
  34. Döhner H, Weisdorf DJ, Bloomfield. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-1152.
  35. Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258-1264.
  36. Döhner H, Wei AH, Montesinos P, et al. Escalated dosing schedules of CC-486 are effective and well tolerated for patients experiencing first acute myeloid leukemia (AML) relapse: results from the phase III QUAZAR AML-001 maintenance trial. Presented at: 2020 American Society of Hematology Virtual Annual Meeting; December 5-8, 2020. Abstract 111.
  37. Azacitidine [prescribing information]. Summit, NJ: Celgene; 2020.
  38. Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383:2526-2537.
  39. Roboz GJ, Wei AH, Ravandi F, et al. Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7014.
  40. Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91:1645-1666.
  41. Gökbuget N, Dombret H, Ribera J-M, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524-1533.
  42. Tisagenlecleucel [prescribing information]. Basel, Switzerland: Novartis; 2020.
  43. Brexucabtagene autoleucel [prescribing information]. Los Angeles, CA: Kite Pharma, Inc.; 2021.
  44. Shah BD, Ghobadi A, Oluwole OO, et al. Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7002.
  45. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401-412.
  46. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias. N Engl J Med. 2013;369:1783-1796.
  47. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393-404.
  48. Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84-91.
  49. Cortes JE, Apperley J, Lomaia E, et al. OPTIC primary analysis: a dose-optimization study of 3 starting doses of ponatinib (PON). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7000.
  50. Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): a covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther. 2017;363:240-252.
  51. Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep. 2019;14:197-205.
  52. Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS One. 2019;14:e0211228.
  53. Caron F, Leong DP, Hillis C, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1:772-778.
  54. Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133:2031-2042.
  55. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874-879.
  56. Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919-1928.
  57. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323-332.
  58. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7500.
  59. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Presented at: European Hematology Association 2021 Virtual Congress; June 9-17, 2021. Abstract LB1900.
  60. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
  61. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7509.
  62. Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787-798.
  63. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432-443.
  64. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.
  65. Lu P, Wang S, Franzen CA, et al. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer. 2021;11:39.
  66. Deng J, Isik E, Fernandes SM, et al. Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31:2075-2084.
  67. Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095-2103.
  68. Wierda WG, Tam CS, Allan JN, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. Presented at: 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 123.
  69. Ghia P, Allan JN, Siddiqi T, et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7501.
  70. Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132:2016-2025.
  71. Ruan J. Approach to the initial treatment of older patients with mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:871-885.
  72. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826-833.
  73. Phillips TJ, Danilov AV, Bond DA, et al. The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7505.
  74. SEER Cancer Statistics Review 1975-2015. Trends in SEER incidence and U.S. mortality using the Joinpoint Regression Program, 1975-2015 with up to five Joinpoints, 1992-2015 with up to four Joinpoints, both sexes by race/ethnicity. seer.cancer.gov/archive/csr/1975_2015/results_merged/sect_19_nhl.pdf. Accessed September 2, 2021.
  75. Lansigan F, Barak I, Pitcher B, et al. The prognostic significance of PFS24 in follicular lymphoma following first-line immunotherapy: a combined analysis of 3 CALGB trials. Cancer Med. 2019;8:165-173.
  76. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42-51.
  77. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33:2516-2522.
  78. Schuster SJ, Dickinson MJ, Dreyling MH, et al. Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7508.
  79. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.
  80. Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: updated dose escalation data. Presented at: 2020 American Society of Hematology Annual Meeting; December 5-8, 2020. Abstract 402.
  81. Clausen MR, Lugtenburg P, Hutchings M, et al. Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: safety profile and antitumor activity. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 7518.
  82. ClinicalTrials.gov. A phase 3 trial of epcoritamab in R/R DLBCL. clinicaltrials.gov/ct2/show/NCT04628494. Accessed September 2, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue